{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:37:37Z","timestamp":1791949057591,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.ijantimicag.2023.106983","type":"journal-article","created":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T11:58:41Z","timestamp":1695556721000},"page":"106983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: A systematic review and expert opinion"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7234-3526","authenticated-orcid":false,"given":"Tommaso","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Novelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Tascini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Stefani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ijantimicag.2023.106983_bib0001","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/cid\/ciw396","article-title":"Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens","volume":"63","author":"Walker","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106983_bib0002","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0003","first-page":"249","article-title":"Trends in antibiotic resistance for over 700,000 Escherichia coli positive urinary tract infections over six years (2014\u20132019) from a university teaching hospital","volume":"74","author":"Ong","year":"2021","journal-title":"Cent European J Urol"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106983_bib0004","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/1120009X.2021.1955203","article-title":"Oral fosfomycin for treating lower urinary tract infections due to multidrug-resistant Escherichia coli in female adolescents","volume":"34","author":"Polat","year":"2022","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0005","doi-asserted-by":"crossref","first-page":"i939","DOI":"10.1136\/bmj.i939","article-title":"Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis","volume":"352","author":"Bryce","year":"2016","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ijantimicag.2023.106983_bib0006","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00467-019-04316-5","article-title":"Multidrug-resistant organisms in urinary tract infections in children","volume":"35","author":"Mahony","year":"2020","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0007","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4103\/UA.UA_104_19","article-title":"Management of urinary tract infection in women: A practical approach for everyday practice","volume":"11","author":"Abou Heidar","year":"2019","journal-title":"Urol Ann"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/1756287219832174","article-title":"Appropriate use of antibiotics: an unmet need","volume":"11","author":"L\u00f3pez Romo","year":"2019","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.ijantimicag.2023.106983_sbref0009","series-title":"In: EAU guidelines on urological infections","first-page":"1","author":"Bonkat","year":"2019"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0010","series-title":"In: EAU guidelines on urological infections","author":"Bonkat","year":"2022"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106983_bib0011","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JU.0000000000000620","article-title":"Fosfomycin trometamol versus comparator antibiotics for the treatment of acute uncomplicated urinary tract infections in women: a systematic review and meta-analysis","volume":"203","author":"Cai","year":"2020","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106983_bib0012","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106983_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106574","article-title":"SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study","volume":"59","author":"Tutone","year":"2022","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106983_bib0014","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/CU9.0000000000000144","article-title":"Antimicrobial susceptibility of bacteria isolated from urine cultures in Southern Turkey","volume":"16","author":"Baran","year":"2022","journal-title":"Curr Urol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3390\/idr14040067","article-title":"Oral fosfomycin formulation in bacterial prostatitis: new role for an old molecule-brief literature review and clinical considerations","volume":"14","author":"Marino","year":"2022","journal-title":"Infect Dis Rep"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2023.106983_bib0016","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/1120009X.2017.1380357","article-title":"Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections","volume":"29","author":"Novelli","year":"2017","journal-title":"J Chemother"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0017","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","article-title":"Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections","volume":"53","author":"Patel","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0018","unstructured":"EUCAST. MIC EUCAST. Available online: https:\/\/mic.eucast.org\/search\/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=100&search%5Bspecies%5D=-1&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50 [accessed 1 September 2022]."},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106983_bib0019","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10156-011-0212-7","article-title":"In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics","volume":"17","author":"Butcu","year":"2011","journal-title":"J Infect Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106983_bib0021","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1128\/AAC.02099-12","article-title":"Fosfomycin synergy in vitro with amoxicillin, daptomycin, and linezolid against vancomycin-resistant Enterococcus faecium from renal transplant patients with infected urinary stents","volume":"57","author":"Descourouez","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106983_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00342-20","article-title":"Oral fosfomycin treatment for enterococcal urinary tract infections in a dynamic in vitro model","volume":"64","author":"Abbott","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106983_bib0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","article-title":"Fosfomycin: an old\u2013new antibiotic","volume":"18","author":"Raz","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"17","key":"10.1016\/j.ijantimicag.2023.106983_bib0024","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s40265-013-0143-y","article-title":"Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.ijantimicag.2023.106983_bib0025","doi-asserted-by":"crossref","first-page":"e01306","DOI":"10.1128\/JCM.01306-20","article-title":"Susceptibility of clinical isolates of Escherichia coli to fosfomycin as measured by four in vitro testing methods","volume":"58","author":"Karlowsky","year":"2020","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106983_bib0026","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ijantimicag.2017.01.020","article-title":"In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens","volume":"49","author":"Mezzatesta","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106983_bib0027","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based combination therapy for \"difficult-to-treat\" gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106983_bib0028","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","article-title":"Resistance to fosfomycin: mechanisms, frequency and clinical consequences","volume":"53","author":"Falagas","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106983_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01982-19","article-title":"Oral fosfomycin efficacy with variable urinary exposures following single and multiple doses against Enterobacterales: the importance of heteroresistance for growth outcome","volume":"64","author":"Abbott","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2023.106983_bib0030","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.ijantimicag.2006.05.019","article-title":"Pharmacokinetic and pharmacodynamic aspects of antimicrobial agents for the treatment of uncomplicated urinary tract infections","volume":"28","author":"Mazzei","year":"2006","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106983_bib0031","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections","volume":"34","author":"Roussos","year":"2009","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.ijantimicag.2023.106983_bib0032","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00464-18","article-title":"Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants","volume":"62","author":"Wenzler","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.ijantimicag.2023.106983_bib0033","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1016\/j.ijantimicag.2023.106983_bib0034","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/antibiotics11111458","article-title":"Fosfomycin pharmacokinetic profile in plasma and urine and quantitative estimation in prostate and seminal vesicles after one and two consecutive doses of oral fosfomycin trometamol in healthy male volunteers","volume":"11","author":"Di Stefano","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0035","first-page":"216","article-title":"Concentrazioni nel siero e nel tessuto prostatico di fosfomicina con fosfomicina-trometamolo, nuovo derivato della fosfomicina con elevata biodisponibilita per somministrazione orale","volume":"3","author":"Borghi","year":"1986","journal-title":"Farm Ter"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0036","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1093\/cid\/cit704","article-title":"Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis?","volume":"58","author":"Gardiner","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106983_bib0037","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.cmi.2017.08.023","article-title":"High interindividual variability in urinary fosfomycin concentrations in healthy female volunteers","volume":"24","author":"Wijma","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0038","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ijantimicag.2019.07.018","article-title":"Urinary antibacterial activity of fosfomycin and nitrofurantoin at registered dosages in healthy volunteers","volume":"54","author":"Wijma","year":"2019","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"10.1016\/j.ijantimicag.2023.106983_bib0039","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000472877","article-title":"Prophylactic chemotherapy with fosfomycin trometamol salt during transurethral prostatic surgery: a controlled multicenter clinical trial","volume":"13","author":"Periti","year":"1987","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106983_bib0040","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00192-021-05013-4","article-title":"Efficacy and safety of quinolones vs. other antimicrobials for the treatment of uncomplicated urinary tract infections in adults: a systematic review and meta-analysis","volume":"33","author":"Yan","year":"2022","journal-title":"Int Urogynecol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106983_bib0041","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/1120009X.2021.1938949","article-title":"Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women - A systematic review and meta-analysis","volume":"34","author":"Konwar","year":"2022","journal-title":"J Chemother"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106983_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106018","article-title":"Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: a systematic review and meta-analysis","volume":"56","author":"Wang","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"17","key":"10.1016\/j.ijantimicag.2023.106983_bib0043","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Huttner","year":"2018","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.ijantimicag.2023.106983_bib0044","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.cmi.2021.05.032","article-title":"Herbal treatment with uva ursi extract versus fosfomycin in women with uncomplicated urinary tract infection in primary care: a randomized controlled trial","volume":"27","author":"G\u00e1gyor","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106983_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1159\/000493368","volume":"101","author":"Wagenlehner","year":"2018","journal-title":"Urol Int"},{"issue":"5","key":"10.1016\/j.ijantimicag.2023.106983_bib0046","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4111\/icu.20200060","article-title":"Acute Cystitis Symptom Score questionnaire for measuring patient-reported outcomes in women with acute uncomplicated cystitis: clinical validation as part of a phase III trial comparing antibiotic and nonantibiotic therapy","volume":"61","author":"Alidjanov","year":"2020","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0047","doi-asserted-by":"crossref","first-page":"h6544","DOI":"10.1136\/bmj.h6544","article-title":"Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial","volume":"351","author":"G\u00e1gyor","year":"2015","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106983_bib0048","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/JU.0000000000000814","article-title":"Antibiotic prophylaxis for the prevention of infectious complications following prostate biopsy: a systematic review and meta-analysis","volume":"204","author":"Pilatz","year":"2020","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106983_bib0049","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00345-017-2163-9","article-title":"Comparison of fosfomycin against fluoroquinolones for transrectal prostate biopsy prophylaxis: an individual patient-data meta-analysis","volume":"36","author":"Roberts","year":"2018","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106983_bib0050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41391-018-0032-2","article-title":"Fosfomycin vs. quinolone-based antibiotic prophylaxis for transrectal ultrasound-guided biopsy of the prostate: a systematic review and meta-analysis","volume":"21","author":"Noreikaite","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106983_bib0051","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/2090598X.2019.1592636","article-title":"Fosfomycin trometamol vs ciprofloxacin for antibiotic prophylaxis before transrectal ultrasonography-guided prostate biopsy: A meta-analysis of clinical studies","volume":"17","author":"Freitas","year":"2019","journal-title":"Arab J Urol"},{"issue":"2","key":"10.1016\/j.ijantimicag.2023.106983_bib0052","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00345-016-1867-6","article-title":"Antimicrobial prophylaxis for transrectal ultrasound-guided prostate biopsy: fosfomycin trometamol, an attractive alternative","volume":"35","author":"Cai","year":"2017","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0053","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1159\/000342370","article-title":"The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate","volume":"89","author":"Ong\u00fcn","year":"2012","journal-title":"Urol Int"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106983_bib0054","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1590\/s1677-5538.ibju.2016.0619","article-title":"Fosfomycin: a good alternative drug for prostate biopsy prophylaxis the results of a prospective, randomized trial with respect to risk factors","volume":"43","author":"Kisa","year":"2017","journal-title":"Int Braz J Urol"},{"issue":"6","key":"10.1016\/j.ijantimicag.2023.106983_bib0055","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.acuro.2014.01.002","article-title":"Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin","volume":"38","author":"Lista","year":"2014","journal-title":"Actas Urol Esp"},{"issue":"3","key":"10.1016\/j.ijantimicag.2023.106983_bib0056","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/iju.13883","article-title":"Use of fosfomycin as targeted antibiotic prophylaxis before prostate biopsy: A prospective randomized study","volume":"26","author":"Van Besien","year":"2019","journal-title":"Int J Urol"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0057","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000502851","article-title":"Efficacy and safety of two fosfomycin regimens as antimicrobial prophylaxis for transrectal prostate biopsy: a randomised study","volume":"103","author":"D'Elia","year":"2019","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0058","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/antibiotics6040024","article-title":"Fosfomycin: pharmacological, clinical and future perspectives","volume":"6","author":"Dijkmans","year":"2017","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0059","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST) EUCAST general consultation on fosfomycin oral (trometamol) breakpoints for Enterobacterales. EUCAST; 2020. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Consultation\/2020\/EUCAST_General_Consultation_on_Fosfomycon_trometamol_2020.pdf [accessed 1 September 2022]"},{"issue":"4","key":"10.1016\/j.ijantimicag.2023.106983_bib0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0924-8579(00)00351-4","article-title":"Treatment of lower urinary tract infection in pregnancy","volume":"17","author":"Krcmery","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.ijantimicag.2023.106983_bib0061","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2014.303","article-title":"Urinary tract infections in older women: a clinical review","volume":"311","author":"Mody","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijantimicag.2023.106983_bib0062","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","article-title":"Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO\u00b7SENS study revisited","volume":"39","author":"Kahlmeter","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106983_bib0063","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1001\/jama.2018.3627","article-title":"Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial","volume":"319","author":"Vall\u00e9e","year":"2018","journal-title":"JAMA"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T21:03:59Z","timestamp":1718658239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923002625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0924857923002625"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106983","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rediscovering the value of fosfomycin trometamol in the era of antimicrobial resistance: A systematic review and expert opinion","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106983"}}